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Abstract
Background: Corticotropin-releasing hormone (CRH) and CRH-related peptide are shown to
modulate uterine contractility through two CRH receptor subtype, CRH-R1 and CRH-R2 during
pregnancy. Through different signaling pathways, CRH-R1 maintains myometrial quiescence
whereas CRH-R2 promotes smooth muscle contractility. We hypothesized that the expression of
CRH receptors in myometrium might be changed during pregnancy and labour.
Method: Immunohistochemistry, Western blot and RT-PCR were used to quantify the cellular
localization, the protein levels and the mRNA variants of both CRH-R1 and CRH-R2 in upper
segment (US) and lower segment (LS) myometrium from nonpregnant and pregnant women at
term before or after labour.
Results: CRH-R1 and CRH-R2 were predominately localized to myometrial smooth muscle cells
in US and LS. The protein level of CRH-R1 in US was significantly down-regulated in pregnancy,
with a further decrease at the onset of labour. However, the expression of CRH-R1 in LS remained
unchanged during pregnancy and labour. No significant changes in CRH-R2 expression were
observed in US or LS. Six variants of CRH-R1, CRH-R1alpha,-R1beta,-R1c, -R1e,-R1f and -R1g,
were identified in nonpregnant and pregnant myometrium. CRH-R2alpha was identified in pregnant
myometrium, whereas CRH-R2beta was identified in nonpregnant myometrium
Conclusion:  CRH-R1 and CRH-R2 are expressed in nonpregnant and pregnant US and LS
myometrium. Changed expression of CRH receptors during labour may underlie the initiation of
uterine contractility during parturition.
Background
During pregnancy and labour the uterus undergoes dra-
matic changes in its contractile activity, which requires
functional differentiation of the different regions of
uterus. The upper segment (US) region of the uterus main-
tains a relaxatory phenotype throughout most of gestation
to accommodate the growing fetus and adopts a contrac-
tile phenotype to cause expulsion of fetus at the onset of
labour, whereas the lower segment (LS) must differentiate
from a contractile phenotype into a relaxatory phenotype
at labour, allowing passage of fetus [1]. It is known that
abnormalities of this process have major clinical implica-
tions, such as preterm labour. However, to date the regu-
latory mechanisms for this process are poorly understood.
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An increasing body of evidence suggests that corticotro-
pin-releasing hormone (CRH) is an important factor in
the regulation of human pregnancy and parturition [2-4].
During human pregnancy, the placenta and fetal mem-
branes produce large amounts of CRH [5,6]. Synthesis of
CRH in these tissues increases exponentially with advanc-
ing gestation and, by term, it is present in high concentra-
tions in the maternal and fetal blood [6-8]. Abnormal
increases or excessive levels of placental CRH are signifi-
cant risk factors for an earlier onset of spontaneous birth
[7,8]. Because of this, CRH has been proposed to regulate
a placental clock that controls a cascade of physiological
events leading to parturition [7]. Although the precise bio-
logical functions of CRH during pregnancy are not well
defined, it appears to exert a number of effects in intrau-
terine tissues. It has been shown to stimulate prostaglan-
din production in placenta and fetal membranes [9-11],
and to enhance estrogen production whilst reduce proges-
terone production in cultured placental trophoblasts
[12,13]. A number of studies indicate that CRH is
involved in the regulation of myometrial contractility dur-
ing pregnancy [14,15].
It has been demonstrated that CRH belongs to a family of
peptides that includes urocortin I (UCNI), urocortin II
(UCNII) and urocortin III (UCNIII) as well as fish uro-
tensin I and frog peptide sauvagine [16]. UCNI, UCNII
and UCNIII have also been identified in human intrauter-
ine tissues including placenta, fetal membrane and myo-
metrium throughout gestation [15,17,18]. All the CRH
family peptides exert their effects through two subtypes of
CRH receptors, termed CRH-R1 and CRH-R2. These
receptors shared 70% homology at amino acid level
[19,20]. Several splice variants of the mRNA for CRH-R1
and CRH-R2 have been found, eight variants for CRH-R1
and three variants for CRH-R2 [20-22]. It has been shown
that both CRH-R1 and CRH-R2 are expressed in human
nonpregnant and pregnant myometrium [23-26]. Current
evidence suggests that CRH-R1 and CRH-R2 activation
exert distinct actions in the regulation of myometrial con-
tractility during pregnancy. CRH-R1 activation up-regu-
lates the expression of constitutive form of nitric oxide
synthase, thereby promoting myometrium quiescence
[27]. In contrast, CRH-R2 activation can activate ERK1/2
and RhoA pathways that actively promote myometrial
contractility [28].
Our hypothesis is that differential expression of CRH-Rs
may be important for regulating the contractile activity of
uterus in the US and LS during pregnancy and labour.
However, studies regarding CRH-R1 and CRH-R2 expres-
sion in human pregnant myometrium have so far been
limited to LS region [23-26]. To date there is a lack of
information about the expression of CRH-Rs within the
US of human myometrium during pregnancy and labour.
The purpose of this study was to determine whether there
were any changes in the expression of CRH-Rs in human
US and LS myometrium during pregnancy and parturi-
tion. We therefore determined the protein levels of CRH-
R1 and CRH-R2 in the US and LS by Western blot analysis
and showed the localization of CRH-Rs in US and LS
myometrium by immunohistochemistry. In addition, the
mRNA splicing variants of CRH-R1 and CRH-R2 were also
identified by RT-PCR.
Methods
Tissue collection
Paired upper and lower uterine segmental myometrial tis-
sues from pregnant and nonpregnant women were col-
lected in Navy General Hospital, the teaching hospital of
Second Military Medical University, Beijing, China.
Approval of this study was granted by human ethic com-
mittee of Navy General Hospital as well as human ethic
committee of Second Military Medical University. Each
patient signed approved informed consent form to partic-
ipate in this study. Nonpregnant (NP) myometrium tis-
sues were obtained from normal cycling patients (n = 8)
undergoing hysterectomy for fibroids.
Pregnant myometrial tissues were collected at cesarean
section from pregnant women at term gestation and were
divided into two groups: (1) term no labour (TNL, 37–41
weeks, n = 10), (2) term labour (TL, 37–41 weeks, n = 9).
Labour was defined as regular contractions (<5 min apart)
plus membrane rupture and cervical dilation (>3 cm)
with no augmentation. Indications for cesarean section
included breech presentation, placenta previa, previous
cesarean section, cephalopelvic disproportion, failure of
labour to progress, fetal distress, or maternal request.
None of the women included in this study had evidence
of underlying disease (e.g. hypertension, diabetes, preec-
lampsia, intrauterine growth restriction, etc.). LS uterine
samples were collected from the upper margin of the LS
uterine incision, while US uterine samples were taken
from just below fundus. The nonpregnant tissues were
taken from the normal part of uterus without fibrosis con-
tamination. Collected samples were placed in phosphate-
buffered saline (PBS) on ice and transported to the labo-
ratory. Myometrial tissues were separated from any sero-
sal or decidual components and then rinsed in PBS,
frozen immediately in liquid nitrogen and stored at -80 C
for Western blot and PCR analysis. Parts of the tissues
were also placed in 10% phosphate buffered formalin for
immunohistochemical analysis.
Immunohistochemistry
Paraffin sections (5 μm) were cut, rehydrated and micro-
waved in citric acid buffer to retrieve antigens. After inhi-
bition of endogenous peroxidases with 3% H2O2,
nonspecific antibody binding was blocked with 10% rab-Reproductive Biology and Endocrinology 2009, 7:43 http://www.rbej.com/content/7/1/43
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bit serum for 30 min. Serial sections were then incubated
with specific antibodies against human CRH-R1 (sc-
12381, Santa Cruz Biotechnology, Santa Cruz, California,
USA) and CRH-R2 (sc-20550, Santa Cruz) (1:500) over-
night at 4°C. The CRH-R1 antibody is directed against an
epitope between amino acid positions 81 and 109 of
CRH-R1 of human origin, where no sequence homology
exists to CRH-R2. The CRH-R2 antibody was raised
against a peptide mapping near the C-terminus of CRH-
R2 of human origin. Mouse antihuman smooth muscle α-
actin-specific monoclonal antibody (Dako Inc. Carpinte-
ria, California) was used to stained the muscle cells. The
bound antibodies were detected with the biotin-streptavi-
din-peroxidase system (UltraSensitive-SP-kit, MaiXin Bio-
technology, Fuzhou, China) and diaminobenzidine
(Sigma) was used as chromogen. Counterstaining was
performed with hemalum. Negative controls were per-
formed by substituting primary antibody with a normal
serum or IgG in same dilution. To confirm the specificity
of primary antibody, preabsorption of the primary anti-
body with a tenfold excess of the blocking peptides sc-
12381P or sc-20550P (Santa Cruz) was performed.
Western blot analysis
Approximately 70 mg of human myometrial tissue was
homogenized in ice-cold lysis buffer consisting of 60 mM
Tris-HCl, 2% sodium dodecyl sulfate (SDS), 10% sucrose,
2 mM phenylmethylsulfonyl fluoride (Merck, Darmstadt,
Germany), 1 mM sodium orthovanadate (Sigma-Aldrich),
10  μg/ml aprotinin (Bayer, Leverkusen, Germany).
Lysates were then quickly sonified in ice bath, boiled 5
min at 95 C, and stored at -80 C until used. Protein con-
centrations were measured using a modified Bradford
assay and samples were diluted in sample buffer (250 mM
Tris-HCl (pH 6.8), containing 4% SDS, 10% glycerol, 2%
β-mercaptoethanol, and 0.002% bromophenol blue) and
boiled for a further 5 min. Samples (50 μg) were separated
on an SDS-8% polyacrylamide gel, and the proteins were
electrophoretically transferred to a nitrocellulose mem-
brane at 300 mA for 1.5 h in a transfer buffer containing
20 mM Tris, 150 mM glycine, and 20% methanol. The
membrane was then blocked in TBS containing 0.1%
Tween-20(TBST) and 5% dried milk powder (wt/vol) for
2 h at room temperature. After three washes with TBST,
the nitrocellulose membranes were incubated with pri-
mary antibody for CRH-R1 or CRH-R2 (1:500) at 4°C
overnight. After another three washes with TBST, the
membranes were incubated with a secondary horseradish
peroxidase-conjugated IgG (1:1000) for 1 h at room tem-
perature and further washed for 30 min with TBST. Immu-
noreactive proteins were visualized using the enhanced
chemiluminescence Western blotting detection system
(Santa Cruz). The light-emitting bands were detected with
X-ray film. The resulting band intensities were quantitated
using an image scanning densitometer (Furi Technology,
Shanghai, China). To control sampling errors, the ratio of
band intensities to β-actin was obtained to quantify the
relative protein expression level.
Total RNA extraction and cDNA synthesis
Total RNA was extracted from the samples of myo-
metrium by a method based on Chomczynski and Sacchi
[29]. Briefly, frozen tissue samples were powdered under
liquid nitrogen and homogenized in 1 ml of TRIzol rea-
gent (Invitrogen, Grand Island, New York, USA). Subse-
quent extraction of total RNA from the tissues was
conducted according to the protocol provided by the
manufacturer. All RNA samples were treated with deoxyri-
bonuclease I (Promega, Biotech. Co Ltd, Beijing, China).
The purity and integrity of the RNA was checked spectro-
scopically and by gel electrophoresis. Two microgram of
total RNA was reverse transcribed using the SuperScript®
first-strand synthesis system (Invitrogen) and stored at -
20°C.
PCR and nested PCR for CRH-R1 and -R2 variants
The specific primers for the amplification of the CRH-R2
variants and CRH-R1α/CRH-R1β were used as described
previously [22,23,30]. The nucleotide sequences of the
primers were as followings: (1) CRH-R2α, sense 5'-
GAGCTGCTCTTGGACGGC-3', antisense 5'-GACAAG-
GGCGATGCGGTA-3'; (2) CRH-R2β, sense 5'-CCCTCAC-
CAACCTCTCAGGTCC-3', antisense 5'-
CAGGTCATACTTCCTCTGCTTGTC-3'; (3) CRH-R2γ,
sense 5'-CTCAAGCAATCTGCCTACCT-3', antisense 5'-
GGCTCACACTGTGAGTAGTT-3'; (4) CRHR1 α/β, sense
5'-GGCAGCTAGTGGTTCGGCC-3', antisense 5'-TCG-
CAGGCACCGGATGCTC-3'. PCR reaction solution con-
sisted of 2.0 μl diluted cDNA, 0.4 μmol/L of each paired
primers, 2.5 mmol/L Mg2+, 250 μmol/L deoxynucleotide
triphosphates, 1 U Taq DNA polymerase (Qiagen, Beijing,
China), and 1× PCR buffer. PCR reaction was set at 94 C
(45 s), 58 C (45 s), 72 C (1 min) in a total 40–80 cycles
with a final extension step at 72 C for 10 min.
Primers for nested PCR were previously described [21-23],
and were designed to distinguish the different variants of
CRH-R1. The nucleotide sequences of the first round
primers were: exons 2–7, sense 5'-TCCGTCTCGTCAAG-
GCCCTTC-3', antisense 5'-GGCTCATGGTTAGCTGGAC-
CAC-3'; exons 9–14, sense 5'-
CCATTGGGAAGCTGTACTACGAC-3', antisense 5'-GCTT-
GATGCTGTGAAAGCTGACAC-3'. The nucleotide
sequences of the second round primers were: exons 2–7,
sense 5'-TGTCCCTGGCCAGCAACATCTC-3', antisense 5'-
AGTGGATGATGTTTCGCAGGCAC-3';exons 9–14, sense
5'-GGGTGTACACCGACTACATCTAC-3', antisense 5'-
TCTTCCGGATGGCAGAACGGAC-3'. RT-products
(cDNA) from tissues were used as template for the fist
round of PCR. After 40 cycles of amplification, 2 μL of theReproductive Biology and Endocrinology 2009, 7:43 http://www.rbej.com/content/7/1/43
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reaction mixture was used for additional 40-cycle amplifi-
cation. The primers used in this second round of amplifi-
cation were internal to the first set of primers.
Ten microliters of the reaction mixture were subsequently
electrophoresed on a 1.5% agarose gel and visualized by
ethidium bromide, using a 100 bp DNA ladder (Invitro-
gen) to estimate the band sizes. As a negative control for
all of the reactions, distilled water was used in place of
cDNA. The identity of the PCR products was confirmed by
sequencing. Sequence data were analyzed using Blast
nucleic acid database searches from the National Centre
for Biotechnology Information (NCBI).
Statistics
Protein expression levels of CRH-R1 and CRH-R2 were
determined by densitometric analysis (Furi Technology,
Shanghai, China). Peak count values were expressed as
densitometric units. The data are presented as mean ±
SEM. All data were tested for homogeneity of variance by
Bartlett's test. The results indicated that the data were nor-
mally distributed. Student's t-test was used in the analysis
of these data. One-way ANOVA with Student-Newman-
Keuls was used for multiple comparisons. A P value < 0.05
was considered statistically significant.
Results
Localization of CRH-R1 and CRH-R2 in non-pregnant and 
pregnant human myometrium
Both CRH-R1 and CRH-R2 were identified in nonpreg-
nant (Fig. 1) and pregnant (Fig. 2) myometrium. Localiza-
tion of CRH-R1 and CRH-R2 showed that these receptors
were highly expressed in the myometrial smooth muscle
in US and LS (Fig. 1A–C and Fig. 2A, B and 2D–F arrow-
head). Positive staining of CRH-R1 and CRH-R2 was also
seen in vascular smooth muscle cells (Fig. 1D and Fig. 2C
arrowheads). Staining in the US and LS was similar in
each of groups and no dramatic changes in overall stain-
ing intensity or localization were observed with preg-
nancy or with labour (Fig. 2). CRH-R1 and CRH-R2
staining was eliminated when antibody was pre-absorbed
by synthetic peptide (Fig. 1E and 1F, respectively).
Pregnancy and labour associated with changes in the 
expression of CRH-R1 and CRH-R2
As expected, Western blot analysis recognized a protein
band of approximately 55 KDa corresponding to CRH-R1
in human myometrium (Fig 3A). A very faint band of
about 47–50 KDa was also observed (Fig 3A). A single
band of about 55 KDa corresponding to CRH-R2 was
identified in human myometrium (Fig 3A). Preabsorption
with corresponding peptides indicated the specificity of
bands (c&d columns of Fig. 3A and 3B).
With US myometrium, the protein level of CRH-R1 was
down-regulated in pregnancy (NP versus TNL, P <0.05,
Fig 4). It was further decreased at the time of labour (TL
versus TNL, P  < 0.05, Fig 4). With LS myometrium,
although there was a trend of decreased CRH-R1 expres-
sion with pregnancy, the difference failed to reach signifi-
cance (Fig 4, NP versus TNL, NP versus TL). No significant
difference in CRH-R1 levels between TNL and TL group
was observed.
For CRH-R2 levels, no significant changes in associated
with pregnancy or labour were found in US and LS myo-
metrium (Fig. 5).
There was no difference in CRH-R1 expression between
US and LS myometrim in NP and TNL samples. Interest-
ingly, in TL samples, the LS myometrium expressed signif-
Immunolocalisation of CRH-R1 and CRH-R2 in nonpregnant  myometrium Figure 1
Immunolocalisation of CRH-R1 and CRH-R2 in non-
pregnant myometrium. The figure shows representative 
sections of (A, B) US myometrium, and (C, D) LS myo-
metrium. Immunostained with antibodies against (A, C) 
CRH-R1 and (B, D) CRH-R2. The primary antibody was 
either substituted with (E) CRH-R1 preabsorption antibody 
or (F) CRH-R2 preabsorption antibody. (G) Representative 
section immunostained with antibody against α-actin. (H) 
Negative control with normal mouse IgG. Original magnifica-
tion × 400 (A-H). CRH-R1-P: CRH-R1 preabsorption. CRH-
R2-P: CRH-R2 preabsorption.Reproductive Biology and Endocrinology 2009, 7:43 http://www.rbej.com/content/7/1/43
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icantly more CRH-R1 when compared with US, in part
due to the significant reduction in CRH-R1 expression in
the US at the labour onset (Fig 4). No significant differ-
ence in CRH-R2 expression between US and LS myomet-
rim was found across all groups (Fig 5).
CRH-R1 and CRH-R2 variants in nonpregnant and 
pregnant myometrium
RT-PCR and nested PCR analysis showed that CRH-R1α,-
R1β,-R1c, -R1e,-R1f and -R1g were identified in nonpreg-
nant as well as pregnant US and LS samples (Fig 6B and
6C). Other CRH-R1 variants were undetected. CRH-R1α
and -R1β were detected in all biopsies from pregnant and
nonpregnant women, whereas CRH-R1c, -R1e,-R1f and -
R1g were not detected in all biopsies. The detection rates
of CRH-R1c, -R1e,-R1f and -R1g was various in NP, TNL
and TL groups. For instance, within US, CRH-R1c was
identified in 1/9TL and 3/10 TNL samples. CRH-R1e was
detected in 2/9 TL and 3/10 TNL biopsies. CRH-R1f and -
R1g were detected in all TL tissues and 4/10 TNL tissues.
Within LS, 3/10 TNL and 4/9 TL tissues for CRH-R1c, 3/10
TNL and 5/9 TL tissues for CRH-R1e, 4/10 TNL and 6/9 TL
samples for CRH-R1f, and 3/10 TNL and 5/9 TL tissues for
CRH-R1g were identified.
CRH-R2 has three variants, termed CRH-R2α, CRH-R2β
and CRH-R2γ [20]. PCR analysis using specific primers for
these CRH-R2 variants resulted in the detection of CRH-
R2α in all of the pregnant myometrial biopsies and CRH-
R2β in all of nonpregnant tissues (Fig 7). We are unable to
detected CRH-R2γ (data not shown).
Discussion
In the present study, we demonstrated that, for the first
time, CRH-R1 and CRH-R2 expression in paired US and
LS samples from pregnant women who were undergoing
labour and not undergoing labour. We found that CRH-
R1 is significantly reduced during labour, however, this
decrease appeared to be restricted to the US region of
uterus.
The presence of CRH-R1 in human myometrium is in
accordance with published data [23-26,31]. However, the
Immunohistochemistry analysis of CRH receptors in myo- metrium from term labour (TL) and term nolabour (TNL)  patients Figure 2
Immunohistochemistry analysis of CRH receptors in 
myometrium from term labour (TL) and term nola-
bour (TNL) patients. The figure shows representative sec-
tions of (A, C) US and (E, G) LS myometrium in TNL group, 
as well as (B, D) US and (F, H) LS myometrium in TL group. 
(A, B, E, F) Immunostained with CRH-R1 antibody. (C, D, G, 
H) Immunostained with CRH-R2 antibody. Original magnifi-
cation × 400 (A-H).
Distribution of CRH-R1 and CRH-R2 in human myometrium  by Western blot analysis Figure 3
Distribution of CRH-R1 and CRH-R2 in human myo-
metrium by Western blot analysis. (A) Western blot 
analysis of CRH-R1. a&b, immunoblotting using CRH-R1 anti-
body; c&d, preabsorption blots. (B) Western blot analysis of 
CRH-2. a&b, immunoblotting using CRH-R2 antibody; c&d, 
preabsorption blots.Reproductive Biology and Endocrinology 2009, 7:43 http://www.rbej.com/content/7/1/43
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studies regarding the presence of CRH-R2 in pregnant
myometrium are not consistent. Stevens et al [24] showed
that CRH-R2 mRNA was detected in the myometrium of
about 28% of the pregnant patients. In nonlabour myo-
metria, CRH-R2 mRNA was undetectable. Wetzka and
coworkers [25] also reported that expression of CRH-R2
mRNA was identified in 4 out of 6 pregnant myometrium
biopsies. The present study as well as our previous study
[23] showed that CRH-R2 mRNA and protein were iden-
tified in all specimens from pregnant and nonpregnant
women investigated.
Some studies had shown pregnancy and labour associated
changes in CRH-Rs expression in LS myometrium [24,31].
However, these studies only determined the mRNA levels
of CRH-Rs. We previously showed that mRNA and protein
levels of either CRH-R1 or CRH-R2 were not significantly
changed in LS myometrium with labour [23]. In present
study, within LS myometrium, no significant changes in
protein level of both CRH-R1 and CRH-R2 were observed
at term labour. However, within the paired US samples,
CRH-R1 but not CRH-R2 was significantly down-regu-
lated during pregnancy and labour.
Increasing body of evidence implicated that CRH exerts
dual roles in the regulation of myometrial contractility
during pregnancy, it maintains quiescence during preg-
nancy and promotes contractility after onset of parturition
[14,15,32]. Current data from cultured myometrial cells
suggested that CRH-R1 and CRH-R2 mediate distinct
effects on the pregnant myometrium. Activation of CRH-
R1 may maintain myometrium quiescence [15,27,32]
whereas CRH-R2 activation promotes myometrial con-
tractility [15,28]. Thus, a significant decrease in CRH-R1
but not CRH-R2 expression at term labour may help to
facilitate contraction of myometrium for delivery fetus. In
addition, it has been implicated that, at the time of labor,
the fundus (US) of the uterus differentiates into the highly
contractile activity during labour whereas LS region main-
tains relatively quiescent state [1]. Our findings that
expression of CRH-R1 was reduced in fundus but not in
LS at the time of labour may support the concept above.
Both CRH-R1 and CRH-R2 exist in several mRNA variants
as results of alternative gene splicing, with eight variants
for CRH-R1 and three variants for CRH-R2 identified to
Western blot analysis of CRH-R1 expression in nonpregnant  and pregnant myometrium Figure 4
Western blot analysis of CRH-R1 expression in non-
pregnant and pregnant myometrium. (A) Representa-
tive protein bands were presented. (B)The histogram shows 
the densitometric unit for each myometrium group. Data 
were expressed as mean ± SEM. *P<0.05, **P<0.01. NP, non-
pregnant group (n = 8); TNL: term nolabour group (n = 10); 
TL: term labour group (n = 9).
Western blot analysis of CRH-R2 expression in nonpregnant  and pregnant myometrium Figure 5
Western blot analysis of CRH-R2 expression in non-
pregnant and pregnant myometrium. (A) Representa-
tive Western blot signals of CRH-R2 band in US and LS 
myometrium from nonpregnant and pregnant women. (B) 
The histogram shows the densitometric unit of CRH-R2 
band for each group. Data were expressed as mean ± SEM. 
NP, nonpregnant group (n = 8); TNL: term nolabour group 
(n = 10); TL: term labour group (n = 9).Reproductive Biology and Endocrinology 2009, 7:43 http://www.rbej.com/content/7/1/43
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date [20-22]. Studies of Hillhouse groups have demon-
strated that four CRH-R1 and two CRH-R2 variants are
identified in pregnant myometrium [33-35]. Our present
studies identified more CRH-R1 variants in nonpregnant
and pregnant myometrium. It seemed that there were no
obvious differences in CRH-R1 variants identified in US
and LS myometrium.
Based on sequence analysis of different CRH-R1 variants
and in vitro transfection studies, it is suggested that CRH-
R1α is the main functional CRH-R1 variant, whereas other
CRH-R1 variants may have various defects in binding or
signaling properties [20,21,34-37] or modify action of
CRH-R1α [38,39]. Hillhouse and Grammatopoulos pro-
posed that the different expression pattern of CRH-R1 var-
iants in different stage of pregnancy may account for, in
part, dual roles of CRH in the regulation of myometrial
contractility during pregnancy [32,40]. In our present
study, there were no obvious differences in the expression
pattern of CRH-R1 variants between TL and TNL group.
To date it is difficult to identify the splicing variants of
CRH-R1 at protein level due to the lack of available anti-
bodies recognizing individual splicing variants. Slomin-
ski's group showed CRH-R1 with different molecular
weight by Western blot analysis in skin cells and proposed
that CRH-R1 proteins with different molecular weight are
dependent on glycosilation level and may also be the
sliced forms of CRH-R1 [21,38,41]. In the present study,
we also identified a very faint band of about 47–50 kDa
and can be eliminated when the antibody was preab-
sorbed with synthetic peptide. However, the characteris-
tics of the band are required to be studied in the future.
Conclusion
Both CRH-R1 and CRH-R2 were expressed in US and LS
myometrium of nonpregnant and pregnant uterus. CRH-
R1 but not CRH-R2 was significantly down-regulated in
PCR analysis of the human CRH-R1 variants in myometrium Figure 6
PCR analysis of the human CRH-R1 variants in myo-
metrium. (A) CRH-R1 has eight different receptor isoforms 
(modification based on the scheme from ref 22). The repre-
sentative results show the nested PCR products of CRH-
R1in which (B) the primers that go across exon 2–7 were 
used, and (C) the primers that go across exon 9–14. Variants 
are distinguished by different molecular weight of amplified 
bands. Bands indicated by arrow 1 can only be CRH-R1β; 
arrow 2 can be CRH-R1α, -R1c, -R1f, or -R1g isoforms; 
arrow 3 are specific for isoform CRH-R1c; arrow 4 can be 
CRH-R1e. Bands indicated with arrow 5 can be CRH-R1α, -
R1β, or -R1c isoforms; arrow 6 indicates CRH-R1f. arrow 7 
indicates CRH-R1g. NP: nonpregnant group; TNL: term nola-
bour group; TL: term labour group; M: molecular weight 
marker. Lane 1,3,5: LS samples. Lane 2,4,6: US samples.
PCR analysis of the human CRH-R2 variants in myometrium Figure 7
PCR analysis of the human CRH-R2 variants in myo-
metrium. CRH-R2 variants were detected with specific 
primers. NP, nonpregnant group; TNL: term nolabour group; 
TL: term labour group; M: molecular weight marker. Lane 
1,3,5: samples of US myometrium. Lane 2,4,6: samples of LS 
myometrium.Reproductive Biology and Endocrinology 2009, 7:43 http://www.rbej.com/content/7/1/43
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US myometrium at the time of labour. Six CRH-R1 vari-
ants were identified in nonpregnant and pregnant US and
LS myometrium. Our findings, the expression of CRH-Rs
in myometrium during pregnancy and labour, are in
accordance with roles of CRH receptors in the regulation
of uterine contractility.
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